In the latest session, Atricure Inc (NASDAQ: ATRC) closed at $22.90 down -4.94% from its previous closing price of $24.09. On the day, 1315349 shares were traded.
Ratios:
For a deeper understanding of Atricure Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.66 and its Current Ratio is at 3.57. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.15.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on October 23, 2023, initiated with a Mkt Outperform rating and assigned the stock a target price of $60.
On September 29, 2023, UBS started tracking the stock assigning a Buy rating and target price of $56.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 01 ’24 when Noznesky Justin J sold 1,500 shares for $30.39 per share. The transaction valued at 45,585 led to the insider holds 72,784 shares of the business.
Dahlquist Karl S. sold 1,885 shares of ATRC for $60,622 on Mar 18 ’24. The Chief Legal Officer now owns 50,954 shares after completing the transaction at $32.16 per share. On Mar 12 ’24, another insider, Noznesky Justin J, who serves as the Chief Mktg & Strategy Officer of the company, sold 1,500 shares for $36.72 each. As a result, the insider received 55,080 and left with 74,284 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.77 while its Price-to-Book (P/B) ratio in mrq is 2.33.
Stock Price History:
Over the past 52 weeks, ATRC has reached a high of $59.61, while it has fallen to a 52-week low of $23.71.
Shares Statistics:
A total of 47.53M shares are outstanding, with a floating share count of 46.71M. Insiders hold about 3.45% of the company’s shares, while institutions hold 97.89% stake in the company.
Earnings Estimates
There are Atara Biotherapeutics, Inc. different market analysts currently analyzing its stock. The consensus estimate for the next quarter is $16.77, with high estimates of $138.20 and low estimates of $20.10.
Analysts are recommending an EPS of between $Healthcare and $Industrials for the fiscal current year, implying an average EPS of $Industrials.
